Drug Information

Drug General Information
Drug ID
D03NLQ
Former ID
DNCL001954
Drug Name
ABT-957
Indication Alzheimer disease [ICD9: 331; ICD10:G30] Phase 1 [524881]
Company
Abbott Laboratories
Target and Pathway
Target(s) Calpain Target Info Modulator [1572591]
KEGG Pathway Protein processing in endoplasmic reticulum
Apoptosis
Alzheimer's disease
Reactome Degradation of the extracellular matrix
WikiPathways Focal Adhesion
Integrated Pancreatic Cancer Pathway
Alzheimers Disease
Integrin-mediated Cell Adhesion
References
Ref 524881ClinicalTrials.gov (NCT02220738) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors. U.S. National Institutes of Health.
Ref 1572591Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.